Nxtera Pharma LtdDealNxera Pharma Ltd collects clinical US$35m...Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568. more ➔
marquetand - pixapay.comDrug developmentResearchers present AI-guided protein desi...Danish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many … more ➔
Amiferia ABVetmedAmferia partners with Biokema expanding in...Swedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology … more ➔
Veronika SaninScreeningConfusion in Germany about useful genetic...The extent to which vested interests can delay innovation can currently be seen in the introduction of screening for the dominantly inherited disease familial hypercholesterolaemia, the benefits of which … more ➔
pixabay.com/SD-PicturesAIAI identifies most effective climate polic...A brand-new AI analysis of 1,500 climate policies across 41 countries between 1998 and 2022 reveals that only 4% achieved significant emission reductions. more ➔
Biopôle SAFinancingVandria closes Series A round at CHF28.3mSwiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing. more ➔
Adcendo ApSpartnershipAdcendo broadens ADC pipeline in US$1bn bi...Danish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region. more ➔
Stefan Navarro, Experimental Biomedicine I / University Hospital Würzburg, GermanyThrombosisEmfret presents novel anticoagulantGerman biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved … more ➔
Medilink TherapeuticsCancerBioNTech: ADC study continues with conditi...Good news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue. more ➔
Bavarian Nordic A/SEMABavarian Nordic A/S applies for EU label e...Danish vaccine maker Bavarian Nordic A/S has submitted data to the EMA that support label extension of its mpox vaccine imvanex indication to include adolescents 12 to 17 years of age. more ➔
Nxtera Pharma Ltd
marquetand - pixapay.com
Amiferia AB
Veronika Sanin
pixabay.com/SD-Pictures
Biopôle SA
Adcendo ApS
Stefan Navarro, Experimental Biomedicine I / University Hospital Würzburg, Germany
Medilink Therapeutics
Bavarian Nordic A/S